MedTrace Logo

Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)

NCT03559582 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 478

Last updated 2022-03-09

No results posted yet for this study

Summary

Major Research Aim: To study novel molecular diagnostics and the pharmacokinetic variability among a spectrum of TB disease states, including severe forms of TB like disseminated TB, TB meningitis and drug resistant TB, among adults and children from multiple international sites.

Conditions

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Scientific Center for Family Health and Human Reproduction Problems, Russia

    collaborator OTHER_GOV

  • Kilimanjaro Christian Medical Centre, Tanzania

    collaborator OTHER

  • Haydom Lutheran Hospital

    collaborator OTHER

  • Mbarara University of Science and Technology

    collaborator OTHER

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER

  • University of Florida

    collaborator OTHER

  • University of Virginia

    lead OTHER

Principal Investigators

  • Scott K Heysell, MD · University of Virginia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-28
Primary Completion
2020-07-31
Completion
2021-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03559582 on ClinicalTrials.gov